Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaglenastat and Talazoparib in mCRPC
NCT04824937Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of telaglenastat in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Massachusetts General Hospital. Planned start Jul 2021; status: withdrawn.
02
Drugs
telaglenastat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04824937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04824937.